Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)

M.D. Anderson Cancer Center logo

M.D. Anderson Cancer Center

Status

Enrolling

Conditions

Pancreatic Neuroendocrine Tumors
Hyperparathyroidism
Multiple Endocrine Neoplasia

Treatments

Other: Genome Sequencing
Other: Data Review

Study type

Observational

Funder types

Other

Identifiers

NCT03053999
PA12-0892

Details and patient eligibility

About

The study aims to identify predictors of disease in patients with hyperparathyroidism (HPTH) who undergo surgery.

Full description

Researchers aim to identify somatic mutations and inherited genetic variants which may help predict the development of PNET in patients with hyperparathyroidism.

Enrollment

53 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • MEN1 patients who have undergone parathyroidectomy and did not develop PNET.
  • MEN1 patients who have undergone parathyroidectomy and had surgical removal of PNET.

Exclusion criteria

N/A

Trial design

53 participants in 1 patient group

Parathyroidectomy Tissue and Data
Description:
Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors. Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
Treatment:
Other: Data Review
Other: Genome Sequencing

Trial contacts and locations

0

Loading...

Central trial contact

Nancy D. Perrier, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems